201520142013201220112010|2009|2008
 
  2009年度

Mukai Y., Shibata H., Nakamura T., Yoshioka Y., Abe Y., Nomura T., Taniai M., Ohta T., Ikemizu S., Nakagawa S., Tsunoda S., Kamada H., Yamagata Y., Tsutsumi Y. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.
J. Mol. Biol., 385:1221–1229, 2009. [PubMed]

Imai S., Yoshida Y., Okamura T., Nagano K., Abe Y., Yoshikawa T., Kamada H., Nakagawa S., Tsunoda S., Tsutsumi Y.
The specific effect of 2-Methoxyestradiol on lymphatic vascular endothelial cells.
Pharmazie., 64(3):214-6, 2009. [PubMed]

Nagano K., Imai S., Mukai Y., Nakagawa S., Abe Y., Kamada H., Tsunoda S., Tsutsumi Y.
Rapid isolation of intrabody candidates by using an optimized non-immune phage antibody library.
Pharmazie., 64(4):238-41, 2009. [PubMed]

Mukai Y., Nakamura T., Yoshioka Y., Tsunoda S., Kamada H., Nakagawa S., Yamagata Y., Tsutsumi Y.
Crystallization and preliminary X-ray analysis of TNF-TNFR2 complex.
Acta. Crystallogr. Sect. F., 65(Pt 3):295-8, 2009. [PubMed]

Nishimori H., Kondoh M., Isoda K., Tsunoda S., Tsutsumi Y., Yagi K.
Silica nanoparticles as hepatotoxicants.
Eur. J. Pharm. Biopharm., 72(3):496-501, 2009. [PubMed]

Nishimori H., Kondoh M., Isoda K., Tsunoda S., Tsutsumi Y., Yagi K.
Influence of 70-nm silica particles in mice with cisplatin or paraquat-induced toxicity.
Pharmazie., 64(6):395-7, 2009.[PubMed]

Yoshikawa T., Sugita T., Mukai Y., Yamanada N., Nagano K., Nabeshi H., Shibata H., Yoshioka Y., Nakagawa S., Kamada H., Tsunoda S., Tsutsumi Y.
The augmentation of intracellular delivery of peptide therapeutics by artificial protein transduction domains.
Biomaterials., 30(19):3318-23, 2009.[PubMed]

Mukai Y., Nakamura T., Yoshioka Y., Shibata H., Abe Y., Nomura T., Taniai M., Ohta T., Nakagawa S., Tsunoda S., Kamada H., Yamagata Y., Tsutsumi Y.
Fast binding kinetics and conserved 3D structure underlie the antagonistic activity of mutant TNF: useful information for designing artificial proteo-antagonists.
J. Biochem., 146(2):167-72, 2009. [PubMed]

Nishimori H., Kondoh M., Isoda K., Tsunoda S., Tsutsumi Y., Yagi K.
Histological analysis of 70-nm silica particles-induced chronic toxicity in mice.
Eur. J. Pharm. Biopharm., 72(3):626-9, 2009..[PubMed]

Kayamuro H., Yoshioka Y., Abe Y., Katayama K., Yoshida T., Yamashita K., Yoshikawa T., Hiroi T., Itoh N., Kawai Y., Mayumi T., Kamada H., Tsunoda S., Tsutsumi Y.
TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant.
Biochem. Biophys. Res. Commun., 384(3):296-300, 2009. [PubMed]

Nabeshi H., Yoshikawa T., Kamada H., Shibata H., Sugita T., Abe Y., Nagano K., Nomura T., Minowa K., Tsunoda S., Tsutsumi Y.
Arsenic trioxide has the inhibitory effect on transmission of human T-cell leukemia virus type 1.
Biol. Pharm. Bull., 32(7):1286-8, 2009. [PubMed]

Kayamuro H., Abe Y., Yoshioka Y., Katayama K., Yoshida T., Yamashita K., Yoshikawa T., Hiroi T., Itoh N., Kawai Y., Kamada H., Nagano K., Tsunoda S., Tsutsumi Y.
The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses.
Biomaterials., 30(29):5869-5876, 2009. [PubMed]

Nomura T., Abe Y., Kamada H., Inoue M., Kawara T., Arita S., Furuya T., Yoshioka Y., Shibata H., Kayamuro H., Yamashita T., Nagano K., Yoshikawa T., Mukai Y., Nakagawa S., Taniai M., Ohta T., Tsunoda S., Tsutsumi Y.
Novel protein engineering strategy for creating highly receptor-selective mutant TNFs.
Biochem. Biophys. Res. Commun., 30;388(4):667-71, 2009. [PubMed]

Shibata H., Yoshioka Y., Abe Y., Ohkawa A., Nomura T., Minowa K., Mukai Y., Nakagawa S., Taniai M., Ohta T., Tsunoda S., Kamada H., Tsutsumi Y.
The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF.
Biomaterials., 30(34):6638-6647, 2009. [PubMed]

Saeki R., Kondoh M., Kakutani H., Tsunoda S., Mochizuki Y., Hamakubo T., Tsutsumi Y., Horiguchi Y., Yagi K.
A novel tumor-targeted therapy using a claudin-4-targeting molecule.
Mol. Pharmacol., 76(4):918-926, 2009. [PubMed]

Morishige T., Yoshioka Y., Inakura H., Watanabe H., Yao X., Tsunoda S., Tsutsumi Y., Mukai Y., Okada N., Nakagawa S.
LIGHT protein suppresses tumor growth by augmentation of immune response.
Immunol. Lett., 127(1):33-38, 2009. [PubMed]

Kamada H., Fugmann T., Neri D., Roesli C.
Improved protein sequence coverage by on resin deglycosylation and cysteine modification for biomarker discovery.
Proteomics., 9(3):783-787, 2009. [PubMed]

堤 康央
蛋白療法の最適化に叶う創薬基盤技術の開発とその評価.
Drug Delivery System., 24(5):514-521, 2009.

Abe Y., Tsunoda S., Tsutsumi Y.
PEGylated tumor necrosis factor-alpha and its muteins.
Biodrug Delivery Systems: Fundamentals, Applications and Clinical Development., Chapter 28, Informa Healthcare, NY, USA, 2009.

長野一也, 阿部康弘, 角田慎一, 堤 康央
プロテオーム解析とタンパク質DDSの設計・評価.
Pharm Tech Japan., 25(13):24-29, 2009.


Copyright (C) 2009 Osaka Univ. Dept. Toxicology All rights reserved.